Published On: Wed, Oct 19th, 2016

Current Price Targets For Intellipharmaceutics International Inc. (IPCI)


Recently stock market analysts have updated their consensus ratings on shares of Intellipharmaceutics International Inc. (IPCI).

Most recent broker ratings

10/12/2016 – Intellipharmaceutics International Inc. had its “buy” rating reiterated by analysts at Brean Capital. They now have a USD 8 price target on the stock.

10/10/2016 – Intellipharmaceutics International Inc. had its “buy” rating reiterated by analysts at Maxim Group. They now have a USD 6 price target on the stock.

05/13/2015 – Intellipharmaceutics International Inc. was downgraded to “hold” by analysts at Zacks.

02/24/2015 – Intellipharmaceutics International Inc. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 16 price target on the stock.

02/24/2015 – Intellipharmaceutics International Inc. had its “equal weight” rating reiterated by analysts at Barclays. They now have a USD 13.4 price target on the stock.

02/24/2015 – Intellipharmaceutics International Inc. was downgraded to “neutral” by analysts at Nomura.

Intellipharmaceutics International Inc. has a 50 day moving average of 2.14 and a 200 day moving average of 1.87. The stock’s market capitalization is 76.75M, it has a 52-week low of 1.41 and a 52-week high of 3.33.

The share price of the company (IPCI) was down -2.91% during the last trading session, with a high of 2.80 and the volume of Intellipharmaceutics International Inc. shares traded was 336514.

IntelliPharmaCeutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.